Cargando…
Immunologic resilience and COVID-19 survival advantage
BACKGROUND: The risk of severe coronavirus disease 2019 (COVID-19) varies significantly among persons of similar age and is higher in males. Age-independent, sex-biased differences in susceptibility to severe COVID-19 may be ascribable to deficits in a sexually dimorphic protective attribute that we...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mosby
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425719/ https://www.ncbi.nlm.nih.gov/pubmed/34508765 http://dx.doi.org/10.1016/j.jaci.2021.08.021 |
_version_ | 1783749892613603328 |
---|---|
author | Lee, Grace C. Restrepo, Marcos I. Harper, Nathan Manoharan, Muthu Saravanan Smith, Alisha M. Meunier, Justin A. Sanchez-Reilly, Sandra Ehsan, Aamir Branum, Anne P. Winter, Caitlyn Winter, Lauryn Jimenez, Fabio Pandranki, Lavanya Carrillo, Andrew Perez, Graciela L. Anzueto, Antonio Trinh, Hanh Lee, Monica Hecht, Joan M. Martinez-Vargas, Celida Sehgal, Raj T. Cadena, Jose Walter, Elizabeth A. Oakman, Kimberly Benavides, Raymond Pugh, Jacqueline A. Letendre, Scott Steri, Maristella Orrù, Valeria Fiorillo, Edoardo Cucca, Francesco Moreira, Alvaro G. Zhang, Nu Leadbetter, Elizabeth Agan, Brian K. Richman, Douglas D. He, Weijing Clark, Robert A. Okulicz, Jason F. Ahuja, Sunil K. |
author_facet | Lee, Grace C. Restrepo, Marcos I. Harper, Nathan Manoharan, Muthu Saravanan Smith, Alisha M. Meunier, Justin A. Sanchez-Reilly, Sandra Ehsan, Aamir Branum, Anne P. Winter, Caitlyn Winter, Lauryn Jimenez, Fabio Pandranki, Lavanya Carrillo, Andrew Perez, Graciela L. Anzueto, Antonio Trinh, Hanh Lee, Monica Hecht, Joan M. Martinez-Vargas, Celida Sehgal, Raj T. Cadena, Jose Walter, Elizabeth A. Oakman, Kimberly Benavides, Raymond Pugh, Jacqueline A. Letendre, Scott Steri, Maristella Orrù, Valeria Fiorillo, Edoardo Cucca, Francesco Moreira, Alvaro G. Zhang, Nu Leadbetter, Elizabeth Agan, Brian K. Richman, Douglas D. He, Weijing Clark, Robert A. Okulicz, Jason F. Ahuja, Sunil K. |
author_sort | Lee, Grace C. |
collection | PubMed |
description | BACKGROUND: The risk of severe coronavirus disease 2019 (COVID-19) varies significantly among persons of similar age and is higher in males. Age-independent, sex-biased differences in susceptibility to severe COVID-19 may be ascribable to deficits in a sexually dimorphic protective attribute that we termed immunologic resilience (IR). OBJECTIVE: We sought to examine whether deficits in IR that antedate or are induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection independently predict COVID-19 mortality. METHODS: IR levels were quantified with 2 novel metrics: immune health grades (IHG-I [best] to IHG-IV) to gauge CD8(+) and CD4(+) T-cell count equilibrium, and blood gene expression signatures. IR metrics were examined in a prospective COVID-19 cohort (n = 522); primary outcome was 30-day mortality. Associations of IR metrics with outcomes in non–COVID-19 cohorts (n = 13,461) provided the framework for linking pre–COVID-19 IR status to IR during COVID-19, as well as to COVID-19 outcomes. RESULTS: IHG-I, tracking high-grade equilibrium between CD8(+) and CD4(+) T-cell counts, was the most common grade (73%) among healthy adults, particularly in females. SARS-CoV-2 infection was associated with underrepresentation of IHG-I (21%) versus overrepresentation (77%) of IHG-II or IHG-IV, especially in males versus females (P < .01). Presentation with IHG-I was associated with 88% lower mortality, after controlling for age and sex; reduced risk of hospitalization and respiratory failure; lower plasma IL-6 levels; rapid clearance of nasopharyngeal SARS-CoV-2 burden; and gene expression signatures correlating with survival that signify immunocompetence and controlled inflammation. In non–COVID-19 cohorts, IR-preserving metrics were associated with resistance to progressive influenza or HIV infection, as well as lower 9-year mortality in the Framingham Heart Study, especially in females. CONCLUSIONS: Preservation of immunocompetence with controlled inflammation during antigenic challenges is a hallmark of IR and associates with longevity and AIDS resistance. Independent of age, a male-biased proclivity to degrade IR before and/or during SARS-CoV-2 infection predisposes to severe COVID-19. |
format | Online Article Text |
id | pubmed-8425719 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Mosby |
record_format | MEDLINE/PubMed |
spelling | pubmed-84257192021-09-09 Immunologic resilience and COVID-19 survival advantage Lee, Grace C. Restrepo, Marcos I. Harper, Nathan Manoharan, Muthu Saravanan Smith, Alisha M. Meunier, Justin A. Sanchez-Reilly, Sandra Ehsan, Aamir Branum, Anne P. Winter, Caitlyn Winter, Lauryn Jimenez, Fabio Pandranki, Lavanya Carrillo, Andrew Perez, Graciela L. Anzueto, Antonio Trinh, Hanh Lee, Monica Hecht, Joan M. Martinez-Vargas, Celida Sehgal, Raj T. Cadena, Jose Walter, Elizabeth A. Oakman, Kimberly Benavides, Raymond Pugh, Jacqueline A. Letendre, Scott Steri, Maristella Orrù, Valeria Fiorillo, Edoardo Cucca, Francesco Moreira, Alvaro G. Zhang, Nu Leadbetter, Elizabeth Agan, Brian K. Richman, Douglas D. He, Weijing Clark, Robert A. Okulicz, Jason F. Ahuja, Sunil K. J Allergy Clin Immunol Covid-19 BACKGROUND: The risk of severe coronavirus disease 2019 (COVID-19) varies significantly among persons of similar age and is higher in males. Age-independent, sex-biased differences in susceptibility to severe COVID-19 may be ascribable to deficits in a sexually dimorphic protective attribute that we termed immunologic resilience (IR). OBJECTIVE: We sought to examine whether deficits in IR that antedate or are induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection independently predict COVID-19 mortality. METHODS: IR levels were quantified with 2 novel metrics: immune health grades (IHG-I [best] to IHG-IV) to gauge CD8(+) and CD4(+) T-cell count equilibrium, and blood gene expression signatures. IR metrics were examined in a prospective COVID-19 cohort (n = 522); primary outcome was 30-day mortality. Associations of IR metrics with outcomes in non–COVID-19 cohorts (n = 13,461) provided the framework for linking pre–COVID-19 IR status to IR during COVID-19, as well as to COVID-19 outcomes. RESULTS: IHG-I, tracking high-grade equilibrium between CD8(+) and CD4(+) T-cell counts, was the most common grade (73%) among healthy adults, particularly in females. SARS-CoV-2 infection was associated with underrepresentation of IHG-I (21%) versus overrepresentation (77%) of IHG-II or IHG-IV, especially in males versus females (P < .01). Presentation with IHG-I was associated with 88% lower mortality, after controlling for age and sex; reduced risk of hospitalization and respiratory failure; lower plasma IL-6 levels; rapid clearance of nasopharyngeal SARS-CoV-2 burden; and gene expression signatures correlating with survival that signify immunocompetence and controlled inflammation. In non–COVID-19 cohorts, IR-preserving metrics were associated with resistance to progressive influenza or HIV infection, as well as lower 9-year mortality in the Framingham Heart Study, especially in females. CONCLUSIONS: Preservation of immunocompetence with controlled inflammation during antigenic challenges is a hallmark of IR and associates with longevity and AIDS resistance. Independent of age, a male-biased proclivity to degrade IR before and/or during SARS-CoV-2 infection predisposes to severe COVID-19. Mosby 2021-11 2021-09-08 /pmc/articles/PMC8425719/ /pubmed/34508765 http://dx.doi.org/10.1016/j.jaci.2021.08.021 Text en Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Covid-19 Lee, Grace C. Restrepo, Marcos I. Harper, Nathan Manoharan, Muthu Saravanan Smith, Alisha M. Meunier, Justin A. Sanchez-Reilly, Sandra Ehsan, Aamir Branum, Anne P. Winter, Caitlyn Winter, Lauryn Jimenez, Fabio Pandranki, Lavanya Carrillo, Andrew Perez, Graciela L. Anzueto, Antonio Trinh, Hanh Lee, Monica Hecht, Joan M. Martinez-Vargas, Celida Sehgal, Raj T. Cadena, Jose Walter, Elizabeth A. Oakman, Kimberly Benavides, Raymond Pugh, Jacqueline A. Letendre, Scott Steri, Maristella Orrù, Valeria Fiorillo, Edoardo Cucca, Francesco Moreira, Alvaro G. Zhang, Nu Leadbetter, Elizabeth Agan, Brian K. Richman, Douglas D. He, Weijing Clark, Robert A. Okulicz, Jason F. Ahuja, Sunil K. Immunologic resilience and COVID-19 survival advantage |
title | Immunologic resilience and COVID-19 survival advantage |
title_full | Immunologic resilience and COVID-19 survival advantage |
title_fullStr | Immunologic resilience and COVID-19 survival advantage |
title_full_unstemmed | Immunologic resilience and COVID-19 survival advantage |
title_short | Immunologic resilience and COVID-19 survival advantage |
title_sort | immunologic resilience and covid-19 survival advantage |
topic | Covid-19 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425719/ https://www.ncbi.nlm.nih.gov/pubmed/34508765 http://dx.doi.org/10.1016/j.jaci.2021.08.021 |
work_keys_str_mv | AT leegracec immunologicresilienceandcovid19survivaladvantage AT restrepomarcosi immunologicresilienceandcovid19survivaladvantage AT harpernathan immunologicresilienceandcovid19survivaladvantage AT manoharanmuthusaravanan immunologicresilienceandcovid19survivaladvantage AT smithalisham immunologicresilienceandcovid19survivaladvantage AT meunierjustina immunologicresilienceandcovid19survivaladvantage AT sanchezreillysandra immunologicresilienceandcovid19survivaladvantage AT ehsanaamir immunologicresilienceandcovid19survivaladvantage AT branumannep immunologicresilienceandcovid19survivaladvantage AT wintercaitlyn immunologicresilienceandcovid19survivaladvantage AT winterlauryn immunologicresilienceandcovid19survivaladvantage AT jimenezfabio immunologicresilienceandcovid19survivaladvantage AT pandrankilavanya immunologicresilienceandcovid19survivaladvantage AT carrilloandrew immunologicresilienceandcovid19survivaladvantage AT perezgracielal immunologicresilienceandcovid19survivaladvantage AT anzuetoantonio immunologicresilienceandcovid19survivaladvantage AT trinhhanh immunologicresilienceandcovid19survivaladvantage AT leemonica immunologicresilienceandcovid19survivaladvantage AT hechtjoanm immunologicresilienceandcovid19survivaladvantage AT martinezvargascelida immunologicresilienceandcovid19survivaladvantage AT sehgalrajt immunologicresilienceandcovid19survivaladvantage AT cadenajose immunologicresilienceandcovid19survivaladvantage AT walterelizabetha immunologicresilienceandcovid19survivaladvantage AT oakmankimberly immunologicresilienceandcovid19survivaladvantage AT benavidesraymond immunologicresilienceandcovid19survivaladvantage AT pughjacquelinea immunologicresilienceandcovid19survivaladvantage AT immunologicresilienceandcovid19survivaladvantage AT letendrescott immunologicresilienceandcovid19survivaladvantage AT sterimaristella immunologicresilienceandcovid19survivaladvantage AT orruvaleria immunologicresilienceandcovid19survivaladvantage AT fiorilloedoardo immunologicresilienceandcovid19survivaladvantage AT cuccafrancesco immunologicresilienceandcovid19survivaladvantage AT moreiraalvarog immunologicresilienceandcovid19survivaladvantage AT zhangnu immunologicresilienceandcovid19survivaladvantage AT leadbetterelizabeth immunologicresilienceandcovid19survivaladvantage AT aganbriank immunologicresilienceandcovid19survivaladvantage AT richmandouglasd immunologicresilienceandcovid19survivaladvantage AT heweijing immunologicresilienceandcovid19survivaladvantage AT clarkroberta immunologicresilienceandcovid19survivaladvantage AT okuliczjasonf immunologicresilienceandcovid19survivaladvantage AT ahujasunilk immunologicresilienceandcovid19survivaladvantage |